Annovis Bio Receives Excellent Safety Rating And Recommendation To Continue Phase III Trial Of Buntanetap For Parkinson's Disease Patients From The Independent Data And Safety Monitoring Board
Portfolio Pulse from Happy Mohamed
Annovis Bio (NYSE: ANVS) receives a positive safety review from the Data and Safety Monitoring Board (DSMB) for its phase III trial of buntanetap, a drug for early Parkinson's Disease patients. The trial enrolled 523 patients in nine months, with a low dropout rate of 6%. Topline results are expected by the end of 2023.
June 20, 2023 | 4:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Annovis Bio's phase III trial of buntanetap receives a positive safety review, with topline results expected by the end of 2023.
The positive safety review from the DSMB for Annovis Bio's phase III trial of buntanetap is a significant milestone for the company. The trial's accelerated enrollment and low dropout rate indicate strong interest and potential for the drug. This news is likely to have a positive short-term impact on ANVS stock price as it demonstrates progress in the development of the drug and brings the company closer to potential approval and commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100